View Exam | PowerPak

1. Which of the below treatment strategies is an option for the management of hepatic veno-occlusive disease (VOD) in the post–hematopoietic stem cell transplantation (HSCT) setting (assuming the presence of pulmonary dysfunction)?

A. Supportive care B. Supportive care + heparin/tissue plasminogen activator (tPA) C. Supportive care + defibrotide D. Supportive care + ursodeoxycholic acid (UDCA)

2. In the setting of VOD prophylaxis, which of the following strategies has been associated with difficult infusion and/or hemorrhagic risk?

A. Danaparoid B. Ursodiol C. Defibrotide D. Sodium heparin/low molecular weight heparin (LMWH)

3. Which of the following is a component of a strategy for developing or facilitating the use of a preferred drug formulary for the management of VOD in HSCT recipients?

A. Consider only clinical efficacy when developing a formulary. B. Avoid consideration of extraneous factors such as hospital- and disease-related costs. C. Develop decision support tools for other healthcare team members. D. Offer education on pharmacologic dosing to pharmacist team members only.

4. Assume you are part of the hematology-oncology team managing a 59-year-old patient with acute myeloid leukemia who has developed VOD with renal dysfunction 2 weeks after completing an allogeneic transplant. A recommendation of supportive care and defibrotide therapy is made at day 15. Which of the following defibrotide doses would you elect to use?

A. 25 mg/kg/d, minimum 14-day schedule B. 25 mg/kg/d, minimum 21-day schedule C. 15 mg/kg/d, minimum 21-day schedule D. 15 mg/kg/d, minimum 14-day schedule

5. Prior exposure to which of the following pharmacologic therapies is associated with an elevated risk for VOD in a cancer patient preparing for transplant?

A. Ruxolitinib B. Pembrolizumab C. Inotuzumab ozogamicin D. Ibritumomab tiuxetan

Scheduled Maintenance to Improve Performance & Reliability

10/17/2024 4:00 PM EST - 10/17/2024 11:59 PM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the below treatment strategies is an option for the management of hepatic veno-occlusive disease (VOD) in the post–hematopoietic stem cell transplantation (HSCT) setting (assuming the presence of pulmonary dysfunction)?

2. In the setting of VOD prophylaxis, which of the following strategies has been associated with difficult infusion and/or hemorrhagic risk?

3. Which of the following is a component of a strategy for developing or facilitating the use of a preferred drug formulary for the management of VOD in HSCT recipients?

5. Prior exposure to which of the following pharmacologic therapies is associated with an elevated risk for VOD in a cancer patient preparing for transplant?

« Return to Activity

Scheduled Maintenance to Improve Performance & Reliability

10/17/2024 4:00 PM EST - 10/17/2024 11:59 PM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the below treatment strategies is an option for the management of hepatic veno-occlusive disease (VOD) in the post–hematopoietic stem cell transplantation (HSCT) setting (assuming the presence of pulmonary dysfunction)?

2. In the setting of VOD prophylaxis, which of the following strategies has been associated with difficult infusion and/or hemorrhagic risk?

3. Which of the following is a component of a strategy for developing or facilitating the use of a preferred drug formulary for the management of VOD in HSCT recipients?

5. Prior exposure to which of the following pharmacologic therapies is associated with an elevated risk for VOD in a cancer patient preparing for transplant?

« Return to Activity

Customers who Purchased
this Activity also Purchased